Japan plans to revise its definition of “vaccines of high development priority.” The Ministry of Health, Labor and Welfare’s (MHLW)…
REGULATORY
Maintain Funding for COVID Pill beyond April: Academic Societies to Govt
Three Japanese academic associations on February 8 submitted a request to Health Minister Keizo Takemi, urging the government to continue public funding for oral COVID-19 medicines beyond April to help keep down patients’ out-of-pocket payments. In Japan, three oral therapies…
To read the full story
Related Article
- Japan to End Public Aid for COVID Drugs at March-End
February 21, 2024
- Academic Societies to Urge Govt to Continue Funding for COVID Pills beyond April
February 5, 2024
- Transitional Pneumovax Program for Age 70 and Up Set to End in March
December 4, 2023
- Keep Public Funding for COVID Drugs to Get through This Winter: Academic Societies
May 25, 2023
- Japan to Offer COVID Drugs for Free until September-End
March 13, 2023
REGULATORY
- FPMAJ Reports Detailed Results of Blanket Self-Inspections for Generic Firms
January 29, 2025
- Celltrion Is Developer of Japan’s Third Stelara Biosimilar in the Wings
January 29, 2025
- MHLW Donates Mpox Vaccine to Congo
January 28, 2025
- LDP-OK’ed Bill for PMD Act Amendment Specifies Launch of Innovative Drug Fund
January 28, 2025
- Opposition Party Member Calls for Chuikyo Reform
January 27, 2025
As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…